Takotsubo Syndrome
Takotsubo syndrome is a known cause of acute but reversible heart failure due to cardiovascular illnesses due to strong emotional stress that may sometimes seem like acute coronary syndrome. Protheragen, with a specific focus on Takotsubo syndrome and other uncommon cardiovascular disease research, strives to provide an end-to-end solution where scientific breakthroughs meet therapeutic innovations.
Introduction to Takotsubo Syndrome
Takotsubo syndrome is a condition that presents with acute regional wall motion abnormalities (RWMA) that can often be confused for an acute myocardial infarction. It is marked by temporary left ventricular systole dysfunction. Individuals, like most those who suffer from myocardial infarction, present with chest pain alongside ST-segment elevation or ischemia signs on the ECG and elevated troponin levels.
Fig.1 Induction of Takotsubo syndrome by stress. (Dong, F., et al., 2023)Pathogenesis of Takotsubo Syndrome
As it stands, the mechanisms believed to be responsible for Takotsubo syndrome include increased circulating plasma catecholamines and their metabolites, sympathetic hyperexcitability, inflammation, microvascular dysfunction, spasm of the epicardial coronary arteries, deficient estrogen, and genetic and thyroid function abnormalities. However, the real etiologic link remains unclear and several factors likely interact. The strongest theory is the one of endogenous adrenergic surge which is intuitive in light of the profound association with sudden stressors, unfavorable physical disease, or general bodily injury.
Fig.2 Mechanisms involved in Takotsubo syndrome. (Singh, T., et al., 2022)Therapeutics Development for Takotsubo Syndrome
| Drug Names | Mechanism of Action | Targets | NCT Number | Research Phase |
|---|---|---|---|---|
| Cyclosporine A | Inhibition of calcineurin-mediated inflammation. | Calcineurin | NCT05946772 | Phase II |
| Adenosine | Adenosine acts on purinergic receptors which results in blood vessel dilation and has anti-arhythmic properties. | A1R | NCT04666454 | Phase IV |
| Beta-blockers | Protect from stressful stimuli and the following surge of catecholamines. | Beta-adrenergic receptor | NCT06509074 | Phase IV |
| α-lipoic acid | Enhance the adrenergic cardiac innervation. | NF-κB | N/A | N/A |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a therapy plan recommendation. For guidance on therapy options, please visit a regular hospital.
Our Services
Equipped with the latest technologies and tools, our multidisciplinary team of scientists and research professionals conduct transformative research. Our comprehensive services cover all aspects of diagnosis, therapeutics, and even disease modeling ranging from target identification and biomarker discovery to preclinical examination. Furthermore, we offer pharmacokinetic studies and drug safety evaluation to foster rapid, reliable, and seamless movement from idea to validation.
Therapeutic Development Services
Animal Model Development Services
Building models of human diseases is an important step towards discovering the mechanisms and strategies of a given disease's pathophysiology. We offer custom animal model development services for Takotsubo syndrome that realistically replicate its physiological and pathological aspects. This allows for the evaluation of disease progression and testing of potential therapeutics.
Optional models:
- Isoproterenol-induced model
- PDE-3 inhibitor-induced model
- Pilocarpine-induced model
- Immobilization (IMO) stress-induced model
- Other models
Development of animal models having genetic alterations in stress and myocardial signaling proteins associated with Takotsubo syndrome.
Optional models:
- Kv1.5-/- model
- Other models
Protheragen is here to help you in groundbreaking research and development in the sphere of rare cardiovascular diseases. Innovative labs, individualized service, and promise in research quality make us the leaders in the research of rare cardiovascular diseases. Reach out to our team now to see how we can work together form your project, or to get additional information about our complete range of services.
References
- Singh, Trisha et al. "Takotsubo Syndrome: Pathophysiology, Emerging Concepts, and Clinical Implications." Circulation 145.13 (2022): 1002-1019.
- Dong, Feng et al. "Takotsubo syndrome is a coronary microvascular disease: experimental evidence." European heart journal 44.24 (2023): 2244-2253.
For research use only, not for clinical use.